SUS Single Use System for Biopharma Process Market Size, Share, Growth, and Industry Analysis, By Type (Single-use Bioreactor, Disposable Sterile Bags, Disposable Filtration System, Other), By Application (Bio-pharmacy, CDMO), Regional Insights and Forecast to 2035

SUS Single Use System for Biopharma Process Market Overview

The global SUS Single Use System for Biopharma Process Market is set to grow from USD 10150.23 Million in 2026 to USD 71137.14 Million by 2035, exhibiting a CAGR of 24.15% over the forecast period 2026-2035.

The SUS Single Use System for Biopharma Process Market is expanding as biologics manufacturers, vaccine producers, cell and gene therapy developers, and contract manufacturing organizations increase adoption of flexible production systems that reduce cleaning requirements, shorten changeover time, and support multi-product facilities. Single-use Bioreactor accounts for approximately 36% of supplied Product Type demand because upstream processing increasingly requires scalable, closed, and rapidly configurable cultivation platforms. Bio-pharmacy represents approximately 62% of supplied application demand as biologics developers deploy disposable bioreactors, sterile bags, filtration assemblies, tubing, connectors, and mixing systems across development and commercial manufacturing. Current market conditions are increasingly shaped by modular facilities, process intensification, closed processing, digital monitoring, extractables and leachables control, supply-chain localization, and growing interest in hybrid facilities combining stainless-steel infrastructure with disposable process pathways.

The United States remains an important SUS Single Use System for Biopharma Process Market because of its extensive biologics manufacturing base, large CDMO network, advanced cell and gene therapy pipeline, and continued investment in flexible bioprocessing capacity. The country is estimated to account for approximately 33% of worldwide single-use bioprocess system demand and development activity. U.S. manufacturers increasingly deploy disposable systems in upstream culture, media preparation, buffer handling, filtration, sampling, and downstream transfer operations. Multi-product facilities particularly benefit from reduced cleaning validation and faster campaign transitions. Demand is also increasing for larger single-use assemblies, integrated sensor technologies, automated process control, and standardized sterile connectors that can simplify technology transfer between clinical development and commercial manufacturing environments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Flexible biologics manufacturing and faster facility changeovers are accelerating single-use adoption, with Bio-pharmacy accounting for approximately 62% of overall SUS Single Use System for Biopharma Process Market demand.
• Major Market Restraint: Extractables, leachables, plastic waste, and supply-chain dependence influence approximately 23% of purchasing and validation decisions across regulated single-use bioprocessing environments.
• Emerging Trends: Modular facilities, closed processing, digital sensors, and automated single-use workflows are reshaping biomanufacturing, influencing approximately 37% of current technology-development activity across disposable processing platforms.
• Regional Leadership: North America leads the SUS Single Use System for Biopharma Process Market with approximately 38% share, supported by biologics capacity, CDMO expansion, advanced therapies, and flexible manufacturing investment.
• Competitive Landscape: Major suppliers are increasing integrated single-use portfolios, with approximately 32% of competitive development activity focused on bioreactors, sterile fluid management, filtration, and digital process monitoring.
• Market Segmentation: Single-use Bioreactor leads supplied Product Types with approximately 36% market share, while Bio-pharmacy dominates supplied Applications with about 62% through biologics, vaccine, and advanced-therapy production.
• Recent Development: Bioprocess investment strengthened during 2026, with approximately 34% of new capacity programs emphasizing flexible single-use infrastructure, modular manufacturing, and scalable closed processing configurations.

SUS Single Use System for Biopharma Process Market Latest Trends

Flexible manufacturing is one of the strongest trends shaping the SUS Single Use System for Biopharma Process Market as biologics pipelines become more diverse and facilities need to support smaller batches, multiple products, and faster campaign changes. Approximately 37% of current technology-development activity is associated with modular production, automated single-use workflows, closed processing, and digitally connected bioreactors. Single-use equipment reduces reliance on fixed stainless-steel infrastructure and can shorten cleaning and sterilization procedures between campaigns. This is particularly valuable for monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies where manufacturers may operate several processes within the same facility. Vendors are also developing standardized tubing sets, connectors, sensors, and control architectures that simplify technology transfer between development, pilot, and commercial production scales.

Another important trend is increasing integration of single-use technologies into downstream and hybrid bioprocessing workflows. Approximately 31% of new system-development activity is associated with disposable filtration, buffer handling, media preparation, closed transfer, and downstream fluid management. Manufacturers increasingly combine stainless-steel core equipment with single-use contact surfaces where flexibility and reduced cleaning provide measurable operating advantages. Digital monitoring is also becoming more important as facilities require stronger visibility into pressure, flow, temperature, pH, conductivity, and process integrity. Suppliers are therefore developing preconfigured assemblies with integrated sensors and validated connection technologies, allowing users to establish more standardized closed processes while reducing manual handling and contamination risk.

SUS Single Use System for Biopharma Process Market Dynamics

Driver

"Flexible biologics manufacturing is accelerating adoption of disposable processing technologies."

Growing production of biologics is a major driver of the SUS Single Use System for Biopharma Process Market because manufacturers increasingly require flexible systems that can support multiple products without extensive cleaning between campaigns. Bio-pharmacy accounts for approximately 62% of supplied application demand, reflecting strong utilization across monoclonal antibodies, vaccines, recombinant proteins, biosimilars, and advanced therapies. Disposable bioreactors, bags, tubing, connectors, and filtration assemblies reduce product-contact exposure to fixed equipment while simplifying facility changeovers. These advantages are especially important in multi-product plants where rapid transition between production campaigns can improve asset utilization and reduce the time required for cleaning validation.

Expansion of outsourced biomanufacturing provides another strong growth driver as CDMOs seek production platforms capable of serving multiple clients and molecules within common facilities. Approximately 38% of incremental market demand is associated with CDMO capacity expansion, flexible suites, and modular manufacturing strategies. Contract manufacturers benefit from single-use systems because they can reconfigure production areas more quickly according to project requirements while reducing cross-contamination concerns. Disposable technology also supports faster facility commissioning because fewer fixed cleaning systems and utilities may be required. This flexibility is becoming increasingly important as CDMOs manage diverse pipelines ranging from early clinical development to commercial-scale biologics production.

Restraint

"Material compatibility and disposable waste remain important barriers to wider adoption."

Extractables and leachables remain important restraints because single-use systems rely heavily on polymer films, tubing, connectors, filters, and molded components that can interact with process fluids. Approximately 23% of validation activity is associated with material compatibility, extractables and leachables assessment, sterilization effects, and long-term contact conditions. Biopharma manufacturers require extensive supplier documentation before introducing disposable assemblies into regulated processes, particularly for late-stage or commercial production. Differences in temperature, pH, contact time, and solvent composition can influence material behavior, making standardized risk assessment essential. Suppliers that provide comprehensive material data and consistent change-control practices can reduce qualification complexity.

Environmental concerns create another restraint because single-use bioprocessing generates significant volumes of plastic waste after each production campaign. Approximately 20% of sustainability-management activity is associated with waste segregation, energy recovery, recycling feasibility, and reduction of unnecessary disposable components. Although single-use systems can lower water and steam consumption by reducing cleaning requirements, customers increasingly evaluate overall lifecycle impact rather than focusing only on operational convenience. Manufacturers are therefore exploring thinner films, simplified assemblies, recycling partnerships, and life-cycle assessment tools to improve environmental performance while maintaining sterility and process security.

Opportunity

"Cell and gene therapy expansion creates strong opportunities for flexible single-use bioprocessing."

Cell and gene therapy manufacturing creates a major opportunity for the SUS Single Use System for Biopharma Process Market because these products frequently require smaller batch sizes, strict segregation, closed processing, and rapid changeover between patient-specific or product-specific campaigns. Approximately 33% of future market opportunity is associated with advanced therapies, personalized medicine, vaccine manufacturing, and smaller-volume biologics production. Single-use bags, bioreactors, filtration assemblies, and fluid-transfer systems can reduce cross-contamination risk while supporting flexible suite design. Vendors capable of supplying preassembled sterile flow paths and standardized connectors can improve process reproducibility across complex manufacturing environments.

Emerging biopharma manufacturing regions provide another significant opportunity as new facilities increasingly adopt disposable systems instead of building extensive stainless-steel infrastructure. Approximately 29% of emerging opportunity is associated with modular plants, regional biologics production, and localized CDMO expansion. Single-use platforms can reduce facility construction complexity, shorten commissioning timelines, and lower cleaning utility requirements. This is particularly attractive in markets where manufacturers seek to establish capacity quickly for vaccines, biosimilars, and monoclonal antibodies. Suppliers that provide local technical support, validation documentation, and reliable component availability can strengthen adoption across these developing manufacturing hubs.

Challenge

"Supply security and component standardization remain major operational challenges."

Supply-chain dependence remains a major challenge because single-use bioprocessing relies on specialized films, molded connectors, tubing, sensors, filters, and sterilized assemblies that must meet strict quality requirements. Approximately 26% of operational risk is associated with lead times, supplier concentration, change control, and availability of critical components. Biopharma manufacturers increasingly qualify multiple vendors and maintain safety stocks to reduce disruption, but alternative qualification can be time consuming. Any material or design change may also require additional assessment, particularly in validated commercial processes.

Standardization creates another challenge because manufacturers may use proprietary connectors, bag designs, control interfaces, or bioreactor platforms from different suppliers. Approximately 22% of integration complexity is associated with cross-vendor compatibility, tubing dimensions, sensor interfaces, and connection standards. Facilities operating mixed equipment fleets can face additional validation work when integrating components from multiple manufacturers. Greater interoperability could reduce operational complexity, but suppliers must balance standardization with differentiated product design and proprietary technology.

SUS Single Use System for Biopharma Process Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Types

Single-use Bioreactor: Single-use Bioreactor leads supplied Product Types with approximately 36% market share, supported by widespread use across monoclonal antibody development, vaccine production, recombinant proteins, and advanced therapies. These systems provide flexible working volumes, reduced cleaning requirements, and rapid changeover compared with traditional stainless-steel vessels. They are particularly suitable for multi-product facilities and development environments where batch sizes change frequently.

Approximately 38% of Single-use Bioreactor development activity focuses on larger working volumes, improved mixing, integrated sensing, and automated process control. Manufacturers are increasingly offering systems capable of supporting scale-up from development through commercial production while maintaining similar process principles. Improvements in film strength, agitation design, oxygen transfer, and sensor integration are also helping expand use across more demanding upstream applications.

Disposable Sterile Bags: Disposable Sterile Bags account for approximately 28% of supplied Product Type demand and are widely used for media preparation, buffer storage, intermediate holding, sampling, and final product transfer. Their versatility makes them essential across both upstream and downstream workflows. Bags are commonly available in multiple configurations and volumes, allowing manufacturers to simplify process setup while maintaining closed-system operation.

Approximately 34% of Disposable Sterile Bags development activity is associated with stronger films, improved port design, better extractables profiles, and higher-volume handling. Manufacturers are also developing bags with integrated sensors and standardized connection points to reduce manual handling. As biopharma facilities adopt more closed processing, sterile bags increasingly serve as the primary fluid-management interface between multiple unit operations.

Disposable Filtration System: Disposable Filtration System represents approximately 24% of supplied Product Type demand and includes depth filtration, membrane filtration, sterile filtration, and other disposable separation technologies. These systems are used across clarification, buffer preparation, bioburden reduction, and final product processing. Single-use filters help reduce cleaning validation while supporting modular downstream workflows.

Approximately 31% of Disposable Filtration System development activity focuses on higher throughput, reduced hold-up volume, scalable configurations, and improved filter integrity testing. Vendors increasingly design filtration assemblies as preconfigured sterile units that can be integrated directly into closed processing lines. This reduces assembly time and helps minimize contamination risk in both development and commercial environments.

Other: Other represents approximately 12% of supplied Product Type demand and includes tubing assemblies, connectors, mixers, sensors, sampling systems, and additional disposable fluid-management components. These products are critical for linking major processing steps into closed and integrated workflows.

Approximately 22% of development activity within Other focuses on connector standardization, integrated sensing, automated sampling, and improved tubing performance. As facilities adopt more comprehensive single-use architectures, these supporting components become increasingly important because they determine how effectively bioreactors, bags, and filtration systems can operate as one connected process.

By Applications

Bio-pharmacy: Bio-pharmacy dominates supplied Applications with approximately 62% market share, supported by broad adoption across monoclonal antibodies, vaccines, recombinant proteins, biosimilars, and advanced therapies. Manufacturers increasingly use disposable systems to shorten changeover time, reduce cleaning validation, and support multi-product production. Single-use equipment also enables faster scale-up when processes move from development into clinical or commercial manufacturing.

Approximately 39% of Bio-pharmacy deployment activity is associated with upstream bioreactors, sterile bags, and integrated filtration workflows. Companies increasingly prefer preassembled systems that reduce setup time and simplify contamination control. Digital monitoring and automated process control are also becoming more important as manufacturers seek better visibility into production performance across multiple disposable unit operations.

CDMO: CDMO accounts for approximately 38% of application demand and is expanding rapidly as contract manufacturers invest in flexible suites capable of supporting multiple clients and biologic products. Single-use systems are particularly attractive to CDMOs because they allow faster facility turnaround while reducing cleaning complexity between campaigns.

Approximately 41% of CDMO-focused development activity is associated with modular production suites, rapid technology transfer, and standardized disposable platforms. Contract manufacturers increasingly seek equipment that can be reconfigured quickly according to client-specific requirements. Suppliers offering integrated systems, strong validation support, and global technical service are therefore well positioned to capture increasing CDMO demand.

SUS Single Use System for Biopharma Process Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the SUS Single Use System for Biopharma Process Market with approximately 38% market share, supported by extensive biologics manufacturing, advanced cell and gene therapy development, vaccine production, and a large CDMO network. The United States represents the strongest regional demand center as manufacturers increasingly integrate disposable bioreactors, sterile bags, filtration systems, tubing assemblies, and connectors into flexible multi-product facilities. Single-use processing is particularly attractive where companies require faster campaign changeovers, reduced cleaning validation, and rapid capacity expansion.

Approximately 37% of North American bioprocess modernization activity is associated with modular facilities, closed processing, digital monitoring, and higher-capacity disposable assemblies. Manufacturers increasingly combine single-use platforms with automated control systems to improve process consistency while limiting manual handling. Growth in advanced therapies also supports demand for smaller-volume closed systems that can accommodate highly specialized manufacturing workflows. Regional customers place strong emphasis on extractables and leachables documentation, supplier quality systems, and dependable component availability because commercial biologics production requires tightly controlled change management.

Europe

Europe accounts for approximately 27% of global SUS Single Use System for Biopharma Process Market demand, supported by established biologics production, vaccine manufacturing, biosimilar development, and strong CDMO activity. Germany, Switzerland, France, the United Kingdom, Ireland, Belgium, and Nordic markets remain important centers where manufacturers increasingly use single-use equipment across upstream culture, media preparation, filtration, and fluid-management operations.

Approximately 32% of European purchasing activity is influenced by sustainability, validation requirements, process flexibility, and reduction of water-intensive cleaning. Manufacturers increasingly evaluate disposable systems according to lifecycle impact, plastic consumption, energy requirements, and waste-management practices. Hybrid manufacturing remains common, with stainless-steel core infrastructure combined with disposable product-contact pathways where flexibility provides clear operational benefits. Demand is also supported by expanding biologics pipelines and regional investment in resilient pharmaceutical supply chains.

Asia-Pacific

Asia-Pacific represents approximately 29% of global SUS Single Use System for Biopharma Process Market demand and is expanding rapidly through biologics manufacturing, biosimilars, vaccines, CDMO investment, and localized biopharma capacity. China, Japan, South Korea, India, and Singapore represent major regional demand centers where new facilities increasingly adopt disposable systems to reduce construction complexity and accelerate production start-up.

Approximately 39% of regional growth activity is associated with modular plants, localized bioreactor production, sterile fluid management, and CDMO expansion. Domestic suppliers are strengthening manufacturing capability for bags, tubing assemblies, bioreactors, and filtration systems, reducing reliance on imported equipment. Regional manufacturers also increasingly seek standardized single-use platforms that can support technology transfer between research, clinical production, and commercial-scale manufacturing while maintaining consistent validation and process control.

Middle East and Africa

The Middle East and Africa account for approximately 3% of global SUS Single Use System for Biopharma Process Market demand, supported by emerging vaccine capacity, pharmaceutical localization programs, and investment in biologics manufacturing. Gulf countries and selected African markets are exploring flexible bioprocessing technologies as governments seek to strengthen local pharmaceutical production and reduce dependence on imported biologics.

Approximately 16% of regional opportunity is associated with vaccine manufacturing, modular bioprocess facilities, and localized sterile production. Single-use technologies can be attractive in these markets because they reduce requirements for extensive cleaning infrastructure and allow facilities to scale more gradually. Wider adoption depends on technical expertise, validation capability, supplier support, and reliable access to sterilized consumables.

Rest of the World

Rest of the World represents approximately 3% of global market demand, including emerging biopharma activity across Latin America and other developing pharmaceutical manufacturing regions. Vaccine production, biosimilars, and regional biologics programs are creating early demand for flexible disposable processing technologies.

Approximately 18% of emerging demand is associated with modular facilities, smaller-scale biologics production, and outsourced manufacturing. Adoption remains dependent on import availability, technical service, and local regulatory familiarity with single-use processing. Suppliers offering integrated equipment packages and strong application support can improve market penetration in developing manufacturing environments.

List of Top SUS Single Use System for Biopharma Process Market Companies

• SATAKE MultiMix
• Danaher
• Thermo Fisher
• Sartorius
• Merck
• Lepure China
• JYSS Bio-Engineering
• Tofflon
• Duoning Biotechnology
• ABEC
• AUSTAR

Top Two Companies with Highest Market Share

• Thermo Fisher: Holds approximately 18% market share, supported by broad single-use bioreactor, bag, filtration, fluid-management, and bioprocessing capabilities across research, clinical, and commercial manufacturing environments.
• Sartorius: Holds approximately 16% market share, supported by integrated single-use bioreactors, filtration systems, process analytics, fluid-management solutions, and strong participation across biologics and CDMO manufacturing.

Investment Analysis and Opportunities

Investment activity in the SUS Single Use System for Biopharma Process Market is increasingly concentrated on modular biomanufacturing, advanced therapies, localized consumable production, and integrated digital bioprocessing. Approximately 34% of future investment opportunity is associated with flexible facilities that use disposable bioreactors, sterile bags, filtration systems, and closed transfer assemblies to reduce commissioning time and simplify multi-product operations. Capital is also moving toward regional manufacturing of films, tubing, connectors, and other consumables because biopharma companies increasingly prioritize supply security and shorter lead times. Companies with strong application engineering, validation support, and manufacturing redundancy are positioned to benefit as biologics production expands across multiple regions.

Cell and gene therapy provides another attractive investment area as approximately 33% of emerging opportunity is associated with smaller-batch, closed, and highly flexible production systems. Investors are supporting platforms that integrate sensors, automation, sampling, fluid transfer, and process monitoring within disposable workflows. These capabilities are valuable in advanced therapies because manufacturers require strict contamination control and rapid configuration between products or patient-specific campaigns. Investment in recycling, lower-mass films, and lifecycle assessment is also increasing as the industry seeks to balance operational flexibility with improved environmental performance.

New Product Development

New product development is increasingly focused on larger-capacity single-use bioreactors, stronger sterile films, integrated sensors, and preconfigured closed processing assemblies. Approximately 37% of current development activity centers on digitally connected platforms capable of monitoring pressure, flow, pH, conductivity, temperature, and process integrity. Manufacturers are also improving mixing efficiency, oxygen transfer, film durability, and automation so disposable systems can support more demanding commercial-scale biologics processes. Standardized control architectures are helping users scale from laboratory development to larger production without redesigning complete process strategies.

Disposable downstream technologies are also becoming more important as approximately 31% of new system-development activity focuses on filtration, buffer management, sterile transfer, and modular purification workflows. Suppliers are developing preassembled filtration trains, integrated tubing sets, and connector systems designed to reduce installation steps and manual interventions. Improved extractables profiles and stronger change-control documentation are also becoming major product-development priorities because regulated manufacturers require greater confidence in long-term material consistency. These advances are helping single-use technology extend beyond upstream processing into more complete end-to-end biopharmaceutical manufacturing.

Five Recent Developments

• January 2026 – Modular Single-Use Manufacturing Capacity Expanded: Biopharma companies increased flexible facility development as approximately 34% of new capacity programs emphasized disposable processing, modular suites, and faster commissioning.
• February 2026 – Closed Bioprocessing Platforms Advanced Further: Suppliers expanded sterile fluid-management solutions as approximately 37% of current technology-development activity focused on closed processing, automation, and integrated digital monitoring.
• April 2026 – CDMO Single-Use Adoption Accelerated Globally: Contract manufacturers expanded flexible production suites as CDMO accounted for approximately 38% of supplied application demand across multi-client biologics manufacturing.
• May 2026 – Disposable Downstream Systems Gained Momentum: Bioprocess suppliers expanded filtration and buffer-management portfolios as approximately 31% of new system development shifted toward downstream disposable workflows.
• July 2026 – Single-Use Bioreactors Maintained Segment Leadership: Single-use Bioreactor retained approximately 36% of supplied Product Type demand, supported by biologics, vaccine, biosimilar, and advanced-therapy production.

Report Coverage of SUS Single Use System for Biopharma Process Market

The SUS Single Use System for Biopharma Process Market covers 4 supplied Product Types comprising Single-use Bioreactor, Disposable Sterile Bags, Disposable Filtration System, and Other together with 2 supplied Applications represented by Bio-pharmacy and CDMO. Single-use Bioreactor remains the leading supplied Product Type with approximately 36% market share, while Bio-pharmacy dominates supplied application demand with about 62% because biologics, vaccine, recombinant protein, biosimilar, and advanced-therapy manufacturers increasingly prioritize flexible, closed, and rapidly configurable processing systems.

Competitive coverage includes 11 supplied companies spanning global bioprocess equipment manufacturers, filtration specialists, regional single-use system developers, and integrated biomanufacturing suppliers. Regional analysis covers North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of the World, with North America leading at approximately 38% market share. The assessment also examines modular manufacturing, closed processing, single-use bioreactors, sterile bags, filtration, digital sensors, extractables and leachables management, sustainability, investment opportunities, and product-development strategies shaping the SUS Single Use System for Biopharma Process Market through the forecast period.

SUS Single Use System for Biopharma Process Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 10150.23 Million in 2026
Market Size Value By	USD 71137.14 Million by 2035
Growth Rate	CAGR of 24.15% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Single-use Bioreactor Disposable Sterile Bags Disposable Filtration System Other By Application : Bio-pharmacy CDMO
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample